Palo Alto, Calif. – February 13, 2014 – Cooley LLP announced today that it advised Revance Therapeutics, Inc. on its $110 million IPO. Revance is a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications. It now trades on the NASDAQ Global Stock Market under the symbol "RVNC."
The Cooley corporate and securities team advising Revance included partners Mark Weeks, chair of Cooley's medical device practice, and Gordon Ho, as well as special counsel Marina Remennik, and associates Rose Standifer, Patty Cheng, Josh Seidenfeld and Sale Kwon. Critical support for the offering was provided by partners Natasha Leskovsek (regulatory), Mark Windfeld-Hansen (tax) and Renee Deming (compensation and benefits).
This offering follows Cooley's record year for capital markets work in 2013 in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date, Cooley has advised on 20 public offerings, including 10 IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.